Inhibikase Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Inhibikase Therapeutics, Inc. (IKT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-26
- Inhibikase Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was -160.00K shares.
- Inhibikase Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 0.00 shares.
- Inhibikase Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was -49.89K shares.
- Inhibikase Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-03-31 was 209.89K shares, a 205.83% increase year-over-year.
- Inhibikase Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 0.00 shares.
- Inhibikase Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 0.00 shares.
- Inhibikase Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 0.00 shares.
- Inhibikase Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-03-26 | ||||
| 2024-12-31 | 0.00 shares 10-K · filed 2025-03-27 | ||||
| 2023-12-31 | 0.00 shares 10-K · filed 2025-03-27 | ||||
| 2022-12-31 | -160.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -160.00K shares derived: sum of 2 quarters · filed 2024-03-27 | -209.89K shares derived: sum of 3 quarters · filed 2024-03-27 | 0.00 shares 10-K · filed 2024-03-27 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -49.89K shares derived: sum of 2 quarters · filed 2022-11-14 | 160.00K shares 10-Q · filed 2022-11-14 | 91.37K shares derived: sum of 4 quarters · filed 2022-11-14 | |
| 2022-06-30 | -49.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 160.00K shares 10-Q · filed 2022-08-12 | 91.37K shares derived: sum of 3 quarters · filed 2022-08-12 | 91.37K shares derived: sum of 4 quarters · filed 2022-08-12 | |
| 2022-03-31 | 209.89K shares 10-Q · filed 2022-05-16 | 141.26K shares derived: sum of 2 quarters · filed 2022-05-16 | 141.26K shares derived: sum of 3 quarters · filed 2022-05-16 | 141.26K shares derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-12-31 | -68.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -68.63K shares derived: sum of 2 quarters · filed 2022-03-31 | -68.63K shares derived: sum of 3 quarters · filed 2022-11-14 | 0.00 shares 10-K · filed 2022-03-31 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-14 | 68.63K shares 10-Q · filed 2021-11-15 | ||
| 2021-08-16 | 27.24K shares 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | 68.63K shares 10-Q · filed 2022-11-14 | |||
| 2021-06-25 | 90.71K shares 10-Q · filed 2021-11-15 | ||||
| 2021-03-31 | 68.63K shares 10-Q · filed 2022-05-16 | ||||
| 2020-09-30 | 0.00 shares 10-Q · filed 2021-11-15 | ||||
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |